In a mouse model, modulation of IL-18 activity by administration of anti-IL-18 antibodies or mesenchymal stem cells overexpressing IL-18 binding protein has been shown to reduce myocardial infarct size [52,53]. Here, IL18 is linked to myocardial infarction.